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Epithelial-mesenchymal transition (EMT) is a conversion that facilitates organ 
morphogenesis and tissue remodeling in physiological processes such as embryonic 
development and wound healing. A similar phenotypic conversion is also detected in 
fibrotic diseases and neoplasia, which is associated with disease progression. EMT in 
cancer epithelial cells often seems to be an incomplete and bi-directional process. In this 
Review, we discuss the phenomenon of EMT as it pertains to tumor development, 
focusing on exceptions to the commonly held rule that EMT promotes invasion and 
metastasis. We also highlight the role of the RAS-controlled signaling mediators, ERK1, 
ERK2 and PI3-kinase, as microenvironmental responsive regulators of EMT. 
 
INTRODUCTION 
Simple epithelia are composed of cohesive sheets of cells connected by tight junctions 
and polarized in an apical-basal orientation relative to an underlying basement membrane 
(BM; Figure 1). The surrounding mesenchymal cells are embedded within the interstitial 
extracellular matrix (ECM); lacking intercellular junctions, they manifest primarily 
anterior-posterior polarity.1,2 These structural differences are reflected in the 
characteristic genes each cell type expresses: epithelial cells express distinct junctional 
proteins like E-cadherin, and epithelial-specific cytoskeletal proteins like cytokeratins, 
while mesenchymal cells express N-cadherin and mesenchymal-specific vimentin3 (Table 
1). 
 
Desmoplasia, the appearance of fibrous, mesenchymal-like tissue in the peritumor 
stroma, is associated with poor clinical outcome.4 Recent gene-profiling experiments 
suggest that the presence of a mesenchymal gene signature in tumors is predictive of poor 
clinical outcome in colorectal, breast and ovarian cancers.5–10 The principal cell types that 
contribute to the desmoplastic stromal reaction and to the mesenchymal gene signature 
are fibroblasts, which reside in the stroma and produce interstitial ECM molecules, and 
myofibroblasts, which produce growth factors, cytokines, and ECM, and which also act 
to contract the ECM. Myofibroblasts have long been thought to derive from fibroblasts, 
but recent studies show that a substantial proportion of these cells are derived from EMT 
associated with tumor progression, tissue fibrosis and other pathologies.8  
  EMT involves fundamental changes in gene expression that disrupt epithelial 
polarity and that establish a mesenchymal phenotype with concomitant alterations in 
cytoskeletal organization, cell adhesion, and ECM production (Figure 2).1,8,11 This 
process of phenotype conversion is well-conserved throughout the vertebrata, having 
emerged more than 500 million years ago.11,12 More recent observations have led to 
suggestions that EMT contributes to the phenotypic conversions observed in tissue 
fibrosis,3,13–17 chronic inflammation,18 similar to conversions that occur in rheumatic 
diseases and cancer progression.1,8,19–23 Several recent reviews have summarized key 
signaling pathways involved in EMT and have probed the link between the tumor 
microenvironment, fibrosis, EMT, and cancer progression.8,24,25 In this Review, we 
expand upon these ideas by analyzing the mechanistic processes involved in this EMT 
conversion as part of the broader function of epithelial plasticity in tumor progression. 
We focus on the role of RAS signaling in epithelial tissue plasticity because EMT in 
cancer is a dynamic and often incomplete process regulated by the microenvironment and 
RAS and its effector pathways, most notably ERK1, ERK2 and PI3-kinase/Akt. 
Surprisingly, these pathways are responsive to the microenvironment even when RAS is 
mutated into an activated form. 
 
 
EMT IN CULTURE IS PART OF AN INTRINSIC EPITHELIAL TUMOR CELL 
PLASTICITY  
 When Boyer and colleagues studied cultured cells26 they first described EMT as a 
morphological change from epithelial-like tumor cell sheets to scattered, fibroblast-like 
cells capable of invading the basement membrane (Figure 3A). EMT has more recently 
been shown to occur during normal mammary gland morphogenesis and seems to be 
required for formation of ducts.27 Since the initial observations, EMT in cultured cancer 
cells has been characterized on the molecular level; altered expression profiles, 
subcellular localizations, and activity levels are now commonly used to identify EMT in 
culture (Table 1).3 EMT in culture can be either stable, i.e., the mesenchymal phenotype 
is sustained after the stimulus provoking the conversion is removed, or reversible, i.e., the 
cells revert, or undergo a mesenchymal-epithelial transition (MET), when the stimulus is 
removed. Experiments that quantitatively define the transient and incomplete phenotypic 
changes often observed in cultured tumor cells provide insight into the dynamic role 
EMT may play in neoplastic processes.    
Insight into the complexity of EMT has been provided by studies that have used 
gene transcription and proteomic microarrays to assess EMT and MET.28 Additional data 
suggest that the gene signatures for EMT and more generally, tumor epithelial cell 
plasticity are controlled by tissue and microenvironmental factors.8 A comparison of 
transcriptional analyses of TGF-β1-induced EMT in EpH4 mouse mammary epithelial 
cells (transient EMT associated with a scattering phenotype) and EMT induced in EpH4 
derivatives such as c-Fos-ER-EpH4 (stable EMT without induction of malignancy) and 
RAS-EpH4 (stable EMT with induction of malignancy) revealed a common EMT gene 
signature distinct from that associated with scattering, metastasis or oncogene expression 
(Figure 4A). Furthermore, a number of the genes in this signature have been linked to 
poor outcome in breast cancer.28  Intriguingly, some changes in gene-expression profiles 
also overlap with those documented to occur during EMT conversion of the medial edge 
epithelial seam in the embryonic palate.  
Figure 4 B,C shows the extent of this overlap and compares expression of genes 
that are upregulated by at least two-fold during EMT of EpH4 mammary cells with those 
altered during EMT in the embryonic palate.29 There are similar but not identical 
 
alterations in the expression of gene sets in EpH4 mammary cells and embryonic palate. 
There is overlap in genes that are down-regulated during EMT of EpH4 cells compared to 
the gene profile altered during palatogenesis: 70% of genes down regulated in EpH4 cell 
EMT-specific are also altered by more than two-fold during palatogenesis (Figure 4D). 
The similarity between these two EMT signatures might result from the important role of 
TGF-β1 in driving mesenchymal conversion of both EpH4 cells28 and the embryonic 
palate medial ridge epithelium.29 Even though an EMT involves acquisition of at least 
some mesenchymal properties, the EMT-specific gene signature of EpH4 cells shares 
surprisingly few gene expression changes in common with stromal signatures. Such gene 
changes include the fibroblast serum response that encompasses genes that are commonly 
upregulated in fibroblasts from different tissues following serum stimulation in culture, 
and which predicts both poor outcome in breast and other cancers and enhances the 
prognostic value of an “invasiveness” gene signature that predicts poor outcome in breast 
cancer.6,17 A limited overlap in altered gene expression is observed between the EMT-
specific EpH4 cell gene signature and tumor stromal signatures such as head and neck 
squamous cell carcinoma (HNSCC)30 and prostate cancer31 (Figure 5). Furthermore, the 
EpH4 mammary cell EMT gene signature bears little resemblance to an EMT signature 
of HNSCC32 (Figure 5). Although these comparisons are limited, gene-signature analysis 
indicates that EMT is a process that is distinct from metastasis or tumorigenesis per se 
and could be tissue and microenvironment-specific, but has some resemblance to the 
embryonic process, at least when driven by a common factor such as TGF-β1.              
These studies illustrate that EMT in cancer is a complex process that seems to be 
a subset of an extensive conversion program.1,33-37 The dynamic nature of tumor 
phenotype inter-conversion is more difficult to capture in vivo and has rarely been 
documented. A conversion of breast tumor ductal epithelial cells into myoepithelial cells 
and myofibroblasts, however, is suggested by both the residual expression of epithelial 
keratin markers in myoepithelial and myofibroblast cells and the simultaneous expression 
of myoepithelial (e.g. K14, K17 and vimentin) and myofibroblast (e.g. vimentin and 
alpha smooth muscle actin) markers.38 Retention of some epithelial and myoepithelial 
markers in “transdifferentiated” myofibroblasts, as well as evidence of non-random X-
chromosome inactivation patterns38 also demonstrate epithelial plasticity towards the 
 
fibroblast phenotype. These results suggest that adult epithelial cells have a capacity to 
acquire aspects of a mesenchymal phenotype and vice versa in culture and in breast 
cancer. The apparent rarity of an EMT in human tumor samples likely reflects its 
transient nature and its possible function as a brief pro-invasion conversion program that 
is required for colonizing distant tissues.   
 
CLINICAL SIGNIFICANCE OF EMT 
Although EMT has been clearly documented in cultured human cancer cell lines and in 
some human tumors, its prevalence in aggressive tumors and its role in clinical 
progression are still controversial.33,39 A clear demonstration of EMT in most human 
neoplastic disease has been compromised by the cellular heterogeneity of most human 
tumors and by the lack of clear mesenchymal and epithelial tumor in solid tumor 
biopsies. Evidence that EMT might be highly localized and transient or limited to specific 
steps in metastatic colonization32,40 further complicates clinical analysis of this process.  
Uncertainty regarding a clinical role for EMT in tumor progression is fueled by the rarity 
of morphological changes observed in primary tumors by pathologists. Nonetheless, a 
number of studies showing that expression of EMT-related genes (Table 1)1,41 are 
associated with the metastatic/invasive phenotype. Furthermore, a recent study that 
compared the gene signature of metaplastic breast cancer with breast ductal carcinoma, 
showed unique downregulation of epithelial genes and upregulation of mesenchymal 
genes in metaplastic breast carcinoma.42 EMT might therefore be a feature of breast 
carcinoma subtypes. These studies justify further assessment of EMT as an essential 
component of malignancy. 
Nevertheless, increased expression of EMT markers has been detected at the 
invasive fronts of aggressive tumors.1 Data illustrate an association between known 
regulators of EMT (e.g. Snail, Twist, Slug) and aggressive tumor behavior in animal 
models and poor clinical outcome in cancer patients, suggesting a role for EMT in tumor 
progression.1,23,43 The pleiotropic nature of EMT regulators such as Snail, make it 
difficult to determine the extent to which they are causative of EMT in human cancer.44  
One approach used to detect diagnostic, tissue-specific EMT markers is to identify gene 
expression alterations associated with conversion in human tumors, animal cancer 
 
models, or cultured cells and then assess whether or not these gene signatures are 
correlated with clinical outcome. Such transcriptional profiling experiments resulted in 
the identification of a ‘wound responsive’ gene signature7 that predicts poor outcome in 
breast cancer patients and that increases the predictive value of other gene signatures for 
poor outcome in this disease. Similarly, identification of key transcriptional alterations 
associated with the response of human breast epithelial cells to organotypic three-
dimensional culture conditions was also predictive of outcome in breast cancer patients.45  
While the prognostic value of an EMT to breast cancer progression per se has to 
our knowledge not been reported, a number of genes in the EpH4 mammary cell 
EMT/metastatic gene signatures and mammary tumor cell signature are associated with 
poor prognosis in breast cancer.28  Comparison of the EMT-specific EpH4 mammary cell 
gene signature has limited overlap with two metastasis/invasion gene signatures that 
predict poor clinical outcome in breast cancer (Figure 5).10,46  More in-depth studies of 
this type could help to clarify the clinical significance of an EMT to tumor progression.      
 
POSSIBLE FUNCTIONS OF EMT DURING TUMOR PROGRESSION 
Numerous studies have shown that blocking the expression or impairing the function of 
EMT-regulating factors blocks migration and invasion in cultured epithelial cells. 
Invasion and metastasis of epithelial tumors, however, can occur in the absence of any 
detectible EMT, and even in the presence of EMT, invasion and metastasis may not 
occur.1 For example, metastasis of some bladder cancer cell lines was associated with 
conversion to an epithelial phenotype (MET) rather than with retention of the 
mesenchymal phenotype,47 while desmoid tumors are mesenchymal and locally invasive 
but do not metastasize.48 EMT can be functionally uncoupled from the processes of 
invasion and metastasis. Conditional expression of TGF-β1 in mouse keratinocytes in the 
presence of a functional TGF-β1 receptor promoted EMT and metastasis in chemically-
induced papilloma; however, expression of a dominant-negative TGF-β1 receptor 
blocked the induction of EMT but did not influence the ability of TGF-β1 to promote 
metastasis.49 Such observations indicate that it might be an oversimplification that EMT 
as responsible only for increased migratory and invasive capacities.   
 
 A broader perspective of the role of EMT in cancer can be gleaned from the 
study of EMT in normal development. Growing evidence suggests that EMT is integral to 
normal tissue repair and renewal processes50–53 and may contribute to fibrosis when these 
processes are sustained or otherwise aberrant.1,8,15,18,54 As predicted by analysis of EMT 
gene signatures, EMT has been documented in keratinocyte migration at wound sites55 
and in response to UV irradiation. EMT also occurs transiently at the tips of growing 
mouse mammary gland branches as they invade the fat pad during branching 
morphogenesis,27 a process that resembles tumor invasion into adjacent tissues. In such 
instances, EMT-related processes coordinate epithelial cell movement rather than 
dissemination. 
Transient EMT in cancer can provide fibroblast-like properties to tumor cells 
even in the absence of complete morphological alteration. Several reports suggest that 
conversion of non-small-cell lung carcinoma (NSCLC) to a mesenchymal phenotype 
affects their sensitivity to mitogens and to anti-proliferative drugs.  For example, EMT in 
NSCLC, which was detected by a mesenchymal gene signature, predicted loss of 
response to epidermal growth factor receptor (EGFR) activation and insensitivity to the 
EGFR inhibitor erlotinib.56,57 Experimental model studies have shown that acquisition of 
resistance to drugs such as tamoxifen is associated with and may even promote EMT.58 
These studies demonstrate that EMT can be associated with changes in responsiveness to 
mitogens and anti-hormone therapy. It is not clear whether these effects are a direct or 
indirect consequence of a phenotypic conversion. EMT could directly affect responses to 
mitogens and hormones as a result of altered expression of specific growth factor 
receptors, such as EGFR. Mesenchymal cells also differ from epithelial cells in their 
expression of transporters, and this could affect sensitivity to specific drugs.59,60  
EMT may also perform key immune modulatory functions during tumor 
progression. For instance, fibroblasts possess distinct immunomodulatory activities; they 
can permit leukocyte infiltration and retention within tissues at wound sites, by 
presenting antigens to the immune system, and by modifying T-cell responses. Thus, 
fibroblasts could act to mask tumor antigens and to protect tumors from immune 
surveillance.61 Fibroblasts produce and respond to a different set of cytokines and growth 
factors than epithelial cells and are more responsive to the mitogenic and motogenic 
 
effects of platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) than 
epithelial cells. These growth factors are abundant in the microenvironment of tissues 
undergoing extensive remodeling as well as in tumors, and transiently or reversibly, EMT 
might facilitate growth of epithelial tumor cells.62 Transient EMT allows epithelial cells 
to temporarily evade the effects of growth-inhibitory factors. Using a tissue 
micropatterning approach, Nelson and coauthors showed that a transient EMT occurred 
in regions of lowest concentration of the branching inhibitor TGF-β1.27 Transient EMT 
may provide the ductal cells with a temporary release from the inhibitory growth effects 
of TGF-β1, and allow response to other mitogens in the microenvironment.63 In 
summary, the likely transient nature of EMT and paucity of mesenchymal markers for 
EMT have limited an assessment of the extent this conversion contributes to tumor 
progression. Microdissection techniques that enable sampling of the tumor edge as well 
as improved imaging resolution in vivo will also contribute in clarifying the role of EMT 
in tumor metastasis.     
   
MOLECULAR PATHWAYS THAT REGULATE EMT 
Identifying the molecular pathways that regulate EMT in cancer cells has been the 
subject of intense investigation.1,19,64–67 While the processes involved in EMT have 
distinct characteristics in different tissues, RAS-regulated ERK1/ERK2 and PI3-kinase 
signaling pathways are increasingly recognized as key mediators of tumor cell plasticity.  
Gene signatures of de-regulated RAS pathways are common in human tumors and these 
as well as other oncogenic pathway signatures have permitted risk stratification in many 
types of human cancers.68,69 
RAS proteins act as switches controlling many downstream signaling pathways 
and are triggered by microenvironmental factors such as growth factors and ECM 
molecules.70–72 Increased expression and/or mutation of RAS is a common early event in 
human tumors.66,71 In breast cancer, mutations that result in increased expression of RAS 
are more common than mutations that result in constitutive activation,73 and increased 
activity of the RAS-regulated downstream mediators, PI3-kinase and ERK1/ERK2, is a 
poor prognostic indicator.74–79 RAS-regulated pathways can induce autonomous, stable 
EMT in mammary epithelial cells. For example, exposing EpH4 cells with activating 
 
RAS mutations to TGF-β1 stimulates autocrine production of mesenchymal factors such 
as PDGF-A, PDGF-B, and the PDGF receptors alpha and beta, which maintain EMT 
even when exogenous TGF-β1 is withheld. In the absence of constitutively activated 
RAS signaling pathways in parental EpH4 mammary cells, TGF-β1 induces an 
incomplete and transient mesenchymal conversion that is reversible when TGF-β1 is 
removed.80,81   
ERK1/ERK2 and PI3-kinase-regulated pathways play central roles in tumor cell 
EMT. PI3-kinase stimulates proliferation, blocks apoptosis, and promotes cadherin 
isotype switching upon exposure to interstitial collagens;65,82 ERK1/ERK2 disassembles 
adherens junctions and induces expression of mesenchymal ECM components such as 
tenascin-C as well as matrix metalloproteinases (MMPs).83,84 Both pathways regulate the 
transcription factors Slug and Snail, which in turn promote EMT by suppressing 
expression of E-cadherin, genes encoding epithelial tight junction components, and 
epithelial-specific cytokeratins; loss of E-cadherin induced by extracellular MMPs can 
induce EMT as well.85–87 Activation of ERK1/ERK2 and PI3-kinase pathways regulate 
tumor suppressive effects of environmental factors such as TGF-β1, promoting growth 
and stabilization of EMT,88 an effect that is achieved by linking TGF-β1 receptor activity 
to PI3-kinase and ERK1/ERK2 signaling pathways.28,49,80 RAS, PI3-kinase, and 
ERK1/ERK2 mediators are controlled through alteration of integrin-responsive signaling 
pathways: β1-integrins modulate the activity of growth factor receptors such as EGFR 
and PDGFR, which activate ERK1/ERK2 and PI3-kinase.89,90 Additionally, the nuclear 
localization of activated ERK1/ERK2, which is required for its effects on gene 
transcription, is regulated by hyaluronan.91 Thus, ECM molecules in combination with 
growth factors present in the tumor microenvironment control the localization and 
activation status of these RAS-effectors thereby determining the precise effect of these 
pathways on tumor cell behavior and differentiation/plasticity (Figure 6).   
   
CONCLUSIONS 
A more-complete definition of how EMT contributes to cancer progression requires 
analysis of EMT during normal tissue renewal and development of mechanistic assays for 
in situ detection of EMT as well as continued identification of effectors of EMT that are 
 
prognostic for tumor outcome. Ras-regulated ERK1/ERK2 and PI3 kinase signaling 
pathways are modulated by elements of the tumor microenvironment suggesting 
functions beyond their well-studied roles in motility and proliferation. Another active 
field involves identification of EMT regulatory pathways in the context of epithelial 
plasticity to identify potential targets for therapy. In parallel, technical advances in 
accurate sampling and visualization of individual cells will enable isolation and analysis 




Figure 1 Common morphological characteristics of epithelial and mesenchymal 
cells. Epithelial morphology is characterized by an apical-basal polarity, contact with a 
basal basement membrane and formation of extensive cell-cell contacts including tight 
junctions. An anterior-posterior polarity is lost if any cell-cell junctions and residency 
within a more unstructured interstitial matrix characterize mesenchymal morphology.   
 
Figure 2 EMT of mammary epithelial cells. Treatment of mouse mammary epithelial 
cells with MMP-3 stimulates breakdown of epithelial structure and acquisition of a 
mesenchymal morphology.  Red, f-actin; blue, DAPI. 
 
Figure 3  Dynamic role of EMT in mammary gland neoplastic processes. EMT 
during mammary tumor progression is postulated to facilitate tumor cell invasion and 
colonization of distant tissues. EMT permits efficient penetration of vessels and escape 
into distant tissues such as the lung or bone. A mesenchymal phenotype might be retained 
or may revert to an epithelial phenotype (MET) depending upon the tissue 
microenvironment. For example, some microenvironments such as those provided by 
bones can offer selective growth for a mesenchymal phenotype while others (e.g. lung) 
may favor growth of an epithelial phenotype. Abbreviations: EMT, epithelial–
mesenchymal transition; MET, mesenchymal– epithelial transition 
 
 
Figure 4 Overlap between the EMT gene signature of EpH4 mammary cells and 
embryonic palate overlap. (A) A Venn diagram illustrates the overlap between the Eph4 
metastasis and EMT gene signatures for both upregulated and downregulated expression 
of genes. These results show that EMT can be distinguished from metastasis as a 
molecular process. (B) A Venn diagram shows the number of upregulated EMT-specific 
genes in Eph4 cells that are also altered in embryonic palate undergoing EMT, and are up 
and down-regulated by at least two fold.  Both EMT processes are in response to TGFβ1.  
Approximately 50% of EMT-specific genes upregulated in EpH4 cells are also 
upregulated during EMT associated with embryonic palate morphogenesis. (C) The table 
identifies the genes that are commonly altered during EpH4 mammary cell and 
embryonic palate EMT. Of the 21 upregulated EpH4 mammary cell EMT genes, 10 are 
increased (+) in embryonic palate undergoing EMT, 8 are not altered (-) and 3 are down 
regulated (arrow). (D) The table shows the number of down-regulated EMT-specific 
genes of EpH4 mammary cells that are commonly altered in embryonic palate 
undergoing EMT.  
 
Figure 5 Comparison of EpH4 mammary cell EMT gene signature with cancer-
related gene signatures. Both upregulated and down regulated EMT-specific genes from 
EpH4 mammary cells were compared with gene-expression profile changes during EMT 
of head and neck squamous cell carcinoma (HNSCC), stromal gene signatures that have 
prognostic value in breast and other cancers, and metastasis invasion gene signatures that 
predict poor outcome in breast cancer. Limited overlap is seen between the EpH4 EMT-
specific gene signature and these cancer-related gene signatures.   
 
Figure 6. Microenvironmental and spatial regulation of signaling pathways 
controlling EMT.  The RAS-ERK1/ERK2 pathway is an example a signaling module 
that is responsive to microenvironment cues and requires specific subcellular localization 
in determining the consequences to gene expression and tumor phenotype. A simplified 
version of this complex process is illustrated in the diagram. Extracellular matrix 
components interact with integrin receptors at the cell surface (step 1) and the affinity of 
this interaction is modified by growth factor-regulated signaling in a process known as 
 
outside-in signaling (step 2). Conversely, the affinity of the integrin:extracellular matrix 
interaction affects growth factor regulated signaling in a process known as outside-in 
signaling (step 3). The collective interactions between integrins and growth factor 
receptors promote the localization and activation of lipid-modified RAS (2) at the inner 
cell membrane leaflet (step 4). Activated RAS then selectively activates kinases such as 
ERK1/ERK2 (3) but also other pathways such as the PI3 kinase/AKT pathway (step 5).  
RAS also blocks the tumor suppressing activity of TGF-β1 (step 6) by linking this  
pathway to ERK1/ERK2 signaling pathways (step 5). This linkage promotes the pro-
invasion properties of TGF-B1. Activated ERK1/ERK2 must translocate to the nucleus or 
cell adhesion sites known as focal contacts to have access to target proteins that regulate 
EMT/motility/invasion. ERK1 and ERK2 regulate gene expression (e.g. MMP-9) further 
modifies the tumor cell microenvironment thereby affecting integrin/growth factor 
receptor signaling pathway activation status. This downstream consequence of 
RAS/ERK1/2 activation and the reversal of Steps 1–5 have profound effects on tumor 
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Figure 2. EMT of mammary epithelial cells.
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Figure 6.  Microenvironmental and spatial regulation of signaling pathways controlling EMT
